PTAB Axes Hypertension Drug IP Involved In Generic Fight
The Patent Trial and Appeal Board has invalidated a United Therapeutics Corp. patent on Tyvaso, its inhalable treatment for pulmonary hypertension, giving a boost to efforts by challenger Liquidia Technologies Inc....To view the full article, register now.
Already a subscriber? Click here to view full article